BioCentury
ARTICLE | Clinical News

Cicletanine: Development discontinued

August 27, 2012 7:00 AM UTC

Gilead discontinued development of cicletanine to treat PAH after a double-blind, international Phase II trial showed that the product missed the primary endpoint of improving 6MWD from baseline to week 12 vs. placebo. Patients received placebo, once- or twice-daily 150 mg oral cicletanine or once-daily 300 mg oral cicletanine with or without stable background PAH therapy. The trial had planned to enroll about 162 patients. Gilead said data will be presented at the European Respiratory Society meeting in Vienna in September. The company declined to provide details regarding future development of cicletanine in other indications. ...